6.695
Scisparc Ltd stock is traded at $6.695, with a volume of 3,226.
It is up +1.06% in the last 24 hours and up +40.95% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$6.625
Open:
$6.5
24h Volume:
3,226
Relative Volume:
0.00
Market Cap:
$3.84M
Revenue:
$856.00K
Net Income/Loss:
$-12.56M
P/E Ratio:
-0.0289
EPS:
-231.4926
Net Cash Flow:
$-4.14M
1W Performance:
+1.59%
1M Performance:
+40.95%
6M Performance:
+42.21%
1Y Performance:
-82.41%
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
SPRC
Scisparc Ltd
|
6.695 | 3.80M | 856.00K | -12.56M | -4.14M | -231.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scisparc Ltd Stock (SPRC) Latest News
SciSparc Ltd.Ordinary Shares (NQ: SPRC - The Chronicle-Journal
SciSparc | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment) - Moomoo
Scisparc posts audited 2025 net loss of USD 12.56 million - Bitget
SciSparc : Amendment to Annual Report by Foreign Issuer (Form 20-F/A) - marketscreener.com
SciSparc Boosts NeuroThera Stake in C$5.4 Million Financing - TipRanks
SciSparc (NASDAQ: SPRC) backs NeuroThera in C$5.4M raise - Stock Titan
SciSparc funds NeuroThera Labs spinoff with CAD 5.4m financing round - AllSci
SciSparc invests C$2.7M in subsidiary NeuroThera financing By Investing.com - Investing.com
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6% - Moomoo
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 - GlobeNewswire
Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement - TheNewswire
SciSparc (SPRC) Gains 1.59% as Shares Hold Firm Above $6 Support ZonePut Call Ratio - vinanet.vn
SciSparc Ltd. (SPRC) Stock Price, News, Quote & History - Yahoo! Finance Canada
NeuroThera Labs Inc. Closes First Tranche of Non-Brokered Private Placement - NewMediaWire
NeuroThera Labs Inc. Closes First Tranche Of Non-Brokered Private Placement - TheNewswire
SciSparc Ltd. (SPRC) stock price, news, quote and history - Yahoo Finance UK
SciSparc Subsidiary NeuroThera Wins Japanese Patent for Novel Pain and Fever Therapy - TipRanks
SciSparc Ltd. (Nasdaq: SPRC) subsidiary gains Japanese patent on novel pain treatment combo - Stock Titan
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination - The Manila Times
SciSparc Subsidiary NeuroThera Receives Japanese Patent for 4-Aminophenol Combination Therapy - Quiver Quantitative
Japanese patent covers SciSparc subsidiary’s pain and fever combo - Stock Titan
NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination - TradingView
SPRC Stock Price, Quote & Chart - ChartMill
SciSparc (SPRC) Slips 0.87% to $6.87 as Biotech Stock Holds Above Key SupportTrend Continuation Trade - dars.gov.et
Scisparc Ltd (SPRC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Scisparc Ltd (SPRC) Stock News Today - TradingKey
SciSparc’s NeuroThera Launches Phase IIb Tourette Trial at Yale Child Study Center - TipRanks
SciSparc (Nasdaq: SPRC) launches Phase IIb SCI-110 Tourette study - Stock Titan
SciSparc’s NeuroThera Opens Yale Site for Phase IIb SCI-110 Tourette Syndrome Trial - Quiver Quantitative
Tourette drug candidate enters Phase IIb with prior 21% tic reduction - Stock Titan
Price to book forward of SciSparc Ltd. – NASDAQ:SPRC - TradingView
SciSparc (SPRC) Slips Slightly as Shares Test Key Support Near $7.11Weak Sell Signals - vinanet.vn
SciSparc (SPRC) Plunges 18.16% — Support at $6.76 Becomes CriticalRegression Channel - Vinanet
SciSparc Announces NeuroThera Labs Achieves Milestone in Quantum-Enabled Clinical Trial Data Analytics Platform - Quiver Quantitative
Quantum clinical analytics milestone at SciSparc (Nasdaq: SPRC) - Stock Titan
SciSparc (SPRC) Drops 4.29% as Shares Test Key Support Near $8.26Retail Sentiment - dars.gov.et
Enterprise value to EBIT forward of SciSparc Ltd. – NASDAQ:SPRC - TradingView
SciSparc (SPRC) Surges Over 70%: Analyzing the Massive RallyHigh Volume Stocks - dars.gov.et
SciSparc Moves Into Agentic AI With New Scientific Advisory Board - TipRanks
Scisparc Ltd. Announces Establishment of Scientific Advisory Board - marketscreener.com
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum - GlobeNewswire
SciSparc (Nasdaq: SPRC) targets agentic AI, advances quantum platform - Stock Titan
Scisparc Ltd (SPRC) Earnings Date & Reports & Earnings News - TradingKey
Scisparc Ltd (SPRC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SciSparc shifts focus to agentic AI market - Investing.com
Scisparc Ltd (SPRC) Balance Sheet - TradingKey
Scisparc Ltd (SPRC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Scisparc Ltd (SPRC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Scisparc Ltd (SPRC) Institutional Confidence - TradingKey
SciSparc shifts focus to agentic AI market By Investing.com - Investing.com Canada
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity - The Manila Times
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):